| __timestamp | Novartis AG | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 10811000 |
| Thursday, January 1, 2015 | 14247000000 | 33001000 |
| Friday, January 1, 2016 | 14192000000 | 64936000 |
| Sunday, January 1, 2017 | 14997000000 | 99909000 |
| Monday, January 1, 2018 | 16471000000 | 127724000 |
| Tuesday, January 1, 2019 | 14369000000 | 161524000 |
| Wednesday, January 1, 2020 | 14197000000 | 182933000 |
| Friday, January 1, 2021 | 14886000000 | 219982000 |
| Saturday, January 1, 2022 | 14253000000 | 278139000 |
| Sunday, January 1, 2023 | 12489000000 | 309799000 |
| Monday, January 1, 2024 | 12566000000 |
Infusing magic into the data realm
In the world of pharmaceuticals, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two industry players: Novartis AG and Ultragenyx Pharmaceutical Inc., from 2014 to 2023.
Novartis AG, a global leader, consistently reported high SG&A expenses, peaking in 2018. Despite a slight decline in recent years, their expenses remained robust, reflecting their expansive operations and market reach.
Ultragenyx, a smaller yet dynamic player, showed a remarkable upward trend. From a modest start in 2014, their SG&A expenses surged by over 2,700% by 2023, indicating aggressive growth and expansion strategies.
This comparison highlights the contrasting strategies of a well-established giant and an ambitious newcomer, offering insights into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.